Takeda Pharmaceutical Company Ltd

GSK's multiple myeloma drug Blenrep seeks FDA approval in combination with Velcade and Pomalyst after market withdrawal in 2022. Based on DREAMM-7 and DREAMM-8 Phase III trials, Blenrep combos showed significant PFS improvements over standard treatments, with a PDUFA date set for July 2025. Expected to compete with BCMA CAR-T therapies like Carvykti and Tecvayli, Blenrep offers simpler IV infusion without premedication or hospitalization.

Asia-Pacific leads in vaccine development with 46% of global prophylactic trials and 31% of therapeutic trials, driven by technological innovations, strategic investments, and regional collaborations. The industry shifts from prophylactic to therapeutic applications, with mRNA and viral vector platforms, genomics, AI, and therapeutic innovations in oncology shaping the future. Challenges include vaccine equity, regulatory complexities, and public hesitancy, but strategic investments and collaborations are reshaping the sector.

Explore Smartkarma's AI-augmented platform with a free Preview Pass to unlock research summaries, follow top analysts, receive personalised alerts, and access analytics and events. Join 55,000+ investors, including top global asset managers.

Denali Therapeutics, led by Dr. Richard Tsai, is developing a PGRN replacement therapy (TAK-594/DNL593) to treat FTD-GRN, aiming to restore PGRN levels in the brain. The company emphasizes the urgent need for support, awareness, and well-tolerated disease-modifying therapies for FTD patients and families. They see their role as both scientists and allies, committed to transparency, collaboration, and empowering the FTD community. The research landscape is encouraging due to rapid scientific progress and increased collaboration, though challenges like FTD's complexity and access to clinical trials remain. Denali and Takeda support AFTD's mission.

AC Immune reported Q3 2024 progress, including advancing its Parkinson’s Phase 2 trial and receiving a CHF 24.6 million milestone payment for Alzheimer’s Phase 2b trial. The company achieved a positive net income of CHF 5.5 million, with a strong cash position of CHF 157.9 million, and aims for continued growth in neurodegenerative disease market.

The article does not contain any readable content for summarization.

HUTCHMED announces Takeda's launch of FRUZAQLA® (fruquintinib) in Japan, the first novel oral targeted therapy for metastatic colorectal cancer in over a decade, triggering a milestone payment to HUTCHMED.

HUTCHMED announces Takeda's launch of FRUZAQLA® (fruquintinib) in Japan, following approval by the Japanese Ministry of Health, Labour and Welfare in September 2024. This milestone triggers a payment to HUTCHMED and marks the first novel oral targeted therapy for metastatic colorectal cancer in Japan in over a decade.

Huntington's disease treatments face challenges due to rarity and trial failures, but recent milestones like Wave's WVE-003, Roche-Ionis' tominersen, uniQure's AMT-130, and PTC Therapeutics' PTC518 offer hope. Prilenia's pridopidine is under EMA review, while Annexon's ANX005 and Sage's dalzanemdor faced setbacks. Despite these, cautious optimism remains for effective treatments.